NO20091375L - Sekvensiell kombinasjonsterapi - Google Patents

Sekvensiell kombinasjonsterapi

Info

Publication number
NO20091375L
NO20091375L NO20091375A NO20091375A NO20091375L NO 20091375 L NO20091375 L NO 20091375L NO 20091375 A NO20091375 A NO 20091375A NO 20091375 A NO20091375 A NO 20091375A NO 20091375 L NO20091375 L NO 20091375L
Authority
NO
Norway
Prior art keywords
combination therapy
sequential combination
related disorders
angiogenesis
administering
Prior art date
Application number
NO20091375A
Other languages
English (en)
Inventor
Rakesh K Jain
Clive R Wood
Daniel T Dransfield
Antonio Arulanandam
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of NO20091375L publication Critical patent/NO20091375L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Nye fremgangsmåter for behandling av angiogenese-relaterte lidelser er beskrevet. Angiogenese-relaterte lidelser behandles ved administrering av et Tie1 ektodomene-bindende middel og et VEGF-antagonist-middel.
NO20091375A 2006-10-17 2009-03-31 Sekvensiell kombinasjonsterapi NO20091375L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85226306P 2006-10-17 2006-10-17
US87573606P 2006-12-19 2006-12-19
PCT/US2007/081621 WO2008048996A2 (en) 2006-10-17 2007-10-17 Sequential combination therapy

Publications (1)

Publication Number Publication Date
NO20091375L true NO20091375L (no) 2009-07-10

Family

ID=39314809

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091375A NO20091375L (no) 2006-10-17 2009-03-31 Sekvensiell kombinasjonsterapi

Country Status (17)

Country Link
US (1) US20080160019A1 (no)
EP (1) EP2073826A4 (no)
JP (1) JP2010506951A (no)
KR (1) KR20090067214A (no)
AU (1) AU2007311092A1 (no)
BR (1) BRPI0717760A2 (no)
CA (1) CA2666714A1 (no)
CR (1) CR10798A (no)
EA (1) EA200900562A1 (no)
EC (1) ECSP099336A (no)
IL (1) IL198026A0 (no)
MA (1) MA30901B1 (no)
MX (1) MX2009004070A (no)
NI (1) NI200900057A (no)
NO (1) NO20091375L (no)
TN (1) TN2009000136A1 (no)
WO (1) WO2008048996A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019267A2 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
US20080260861A1 (en) * 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
JP2013528570A (ja) * 2010-03-31 2013-07-11 ユニベルシテ ドゥ ジュネーブ 安定化された抗体調製物およびその使用
US20150003204A1 (en) * 2013-06-27 2015-01-01 Elwha Llc Tactile feedback in a two or three dimensional airspace
US9804675B2 (en) 2013-06-27 2017-10-31 Elwha Llc Tactile feedback generated by non-linear interaction of surface acoustic waves

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342221B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
WO2005019267A2 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
EP1789451A4 (en) * 2004-08-12 2009-12-02 Dyax Corp TIE COMPLEX BINDING PROTEINS
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
MX2009004070A (es) 2009-04-27
EP2073826A2 (en) 2009-07-01
WO2008048996A9 (en) 2008-09-12
AU2007311092A1 (en) 2008-04-24
JP2010506951A (ja) 2010-03-04
ECSP099336A (es) 2009-06-30
NI200900057A (es) 2010-02-02
TN2009000136A1 (en) 2010-10-18
CA2666714A1 (en) 2008-04-24
IL198026A0 (en) 2011-08-01
US20080160019A1 (en) 2008-07-03
WO2008048996A3 (en) 2008-07-03
MA30901B1 (fr) 2009-11-02
EP2073826A4 (en) 2010-12-15
BRPI0717760A2 (pt) 2013-11-12
EA200900562A1 (ru) 2009-10-30
WO2008048996A2 (en) 2008-04-24
KR20090067214A (ko) 2009-06-24
CR10798A (es) 2009-06-09

Similar Documents

Publication Publication Date Title
NO20091375L (no) Sekvensiell kombinasjonsterapi
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
DK2245037T3 (da) Nye forbindelser og fremgangsmåder for terapi
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
MX2009012623A (es) Moduladores de cinasa heterociclicos.
CR9874A (es) Dipeptidyl peptidase inhibitors for treating diabetes
MX2009008132A (es) Terapia de combinacion con inhibidores de angiogenesis.
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
MX2012000817A (es) Tratamiento para desordenes del higado con inhibidores pi3k.
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
BRPI0908276B8 (pt) uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
DK2473510T3 (da) Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
MA32934B1 (fr) Combinaisons inhibitrices hsp90
BRPI0906094B8 (pt) composto
EA201101568A1 (ru) Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
ATE479678T1 (de) Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
DK2310003T3 (da) Inhibitorer af Carnitin-Palmitoyl-Transferase-1 til behandling og forebyggelse af lidelser forårsaget af delipidering af neuralt væv

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application